Skip to content
Syenza News
  • Innovative Tech
  • Diseases
  • Health Policy
  • HTA
  • Data Analysis
  • Clinical Practice
  • Contributors
BACK TO MAIN SITE

MR-107A-02: Revolutionizing Non-Opioid Pain Man...

By Rene Pretorius

May 12, 2025

Viatris Inc.
FDA AI Drug Approval
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
Advancing Early Childhood Health: PureHealth’s Partnership with Abu Dha...
Toripalimab Evidence Journey in Cancer Care
Cancer Control Month 2025: Key Takeaways from President Trump’s National Call...
Oral Cancer in East Africa: The Need for Early Detection
Oral Health in Africa: Promoting Collaborative Solutions
Global Partnerships SCD in Africa
Strengthening Africa Health Partnership
The Urgent Need for Cancer Screening in South Africa
Capvaxive Vaccine Approval
« Previous 1 2 3 4 5 … 16 Next »

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.
PARTNER WITH US
schedule a meeting

SPEAK WITH US

+1 617 219 9400

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

WRITE US

inquiry2023@syenza.com

JOIN NEWSLETTER

This is required.
This is required.
This is required.

SERVICES

  • HEOR
  • Global Market Access
  • Dynamic Intelligence
  • Glossary of Terms
  • Advanced Degrees

QUICK LINKS

  • About
  • Case Studies
  • Insights
  • Art of Science
  • Careers
  • Contact Us
  • Copyright Notice
  • Privacy Policy
  • Terms & Conditions
schedule a meeting
LINKEDIN
TWITTER
© 2026 Syenza™. All rights reserved.

Made with heart by Frogiez

schedule a meeting